Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Beijing Centergate Technologies (holding) Co., Ltd. (000931.SZ)
Beijing, CN
Beijing Centergate Technologies (holding) Co., Ltd. is a multifaceted corporation with a presence in both domestic Chinese and international markets. Its principal activities include the manufacturing and distribution of pharmaceuticals, undertaking construction projects, developing real estate, and providing property management services. The company's pharmaceutical division offers a diverse range of medicinal products, such as huasu west-ground iodine, fesser phenylcycline hydrochloride, bosu fuma acid bisolol, yuanji beni flat hydrochloric acid, and naloxone hydrochloride, along with various tablets and capsules like five plus biochemical and aramol quramado. In addition to traditional medicines, Beijing Centergate Technologies produces specialized oral and mucous membrane repair and health products, encompassing toothpaste, mouthwash, sprays, and dental equipment. These items are designed to address issues like ulcers, burns, mechanical damage, and support post-operative healing. Furthermore, the company supplies nutritional products and food-grade raw materials, including fruit enzymes, imported fungella enzymes, beneficial probiotics, and soda. Beyond its operational segments, the firm also allocates investments to high-tech sectors such as software, communications and electronic engineering, biomedicine, and other areas within the life sciences. Established in Beijing, China, in 1999, the company remains headquartered in its founding city.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.10% | -3.89% | -11.39% | -19.69% | -18.92% | -13.76% | -19.08% | -29.17% | -42.47% | -46.90% | -84.75% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Real Estate - Services: +11.2%-4.4% Q1'26: -23.4% (vs Q1'25)
-
EPS growth Real Estate - Services: +25.9%-10.4% Q1'26: -203.3% (vs Q1'25)
-
FCF margin FCF growth · Real Estate - Services: +32.2%-6.0% Q1'26: +9.4% (vs Q1'25)
-
EBIT margin Real Estate - Services: +23.7%+6.0% Q1'26: +2.1% (vs Q1'25)
-
ROIC Real Estate - Services: +4.3%+3.1% Q1'26: +1.4% (vs Q1'25)
-
Share dilution Real Estate - Services: +0.0%+0.0% Q1'26: -0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Real Estate - Services: 1.88×3.42× Q1'26: 29.75× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|
| Revenue |
2.28B
est: 2.32B (-1.9%)
|
2.53B
est: 2.56B (-1.0%)
|
2.42B
est: 2.88B (-15.8%)
|
3.25B
3.25B – 3.25B
+13.0% YoY
|
| EBITDA |
319.75M
est: 262.28M (+21.9%)
|
375.02M
est: 613.66M (-38.9%)
|
340.35M
est: 689.92M (-50.7%)
|
779.37M
779.37M – 779.37M
+13.0% YoY
|
| EBIT |
145.40M
est: 87.98M (+65.3%)
|
175.49M
est: 407.75M (-57.0%)
|
146.11M
est: 458.42M (-68.1%)
|
517.85M
517.85M – 517.85M
+13.0% YoY
|
| Net Income |
48.57M
est: -30.13M (+261.2%)
|
53.59M
est: 75.31M (-28.8%)
|
47.89M
est: 97.91M (-51.1%)
|
135.56M
135.56M – 135.56M
+38.5% YoY
|
| SGA |
879.06M
est: 870.17M (+1.0%)
|
1.02B
est: 1.02B (+0.2%)
|
1.12B
est: 1.14B (-1.9%)
|
1.29B
1.29B – 1.29B
+13.0% YoY
|
| EPS |
0.06
est: -0.04 (+262.0%)
|
0.07
est: 0.10 (-29.0%)
|
0.06
est: 0.13 (-51.1%)
|
0.18
0.18 – 0.18
+38.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 2/5 | 4/5 | 2/5 | 3/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-28 | B- | 2/5 | 4/5 | 2/5 | 3/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-27 | B- | 2/5 | 4/5 | 2/5 | 3/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | B- | 2/5 | 4/5 | 2/5 | 3/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-25 | B- | 2/5 | 4/5 | 2/5 | 3/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | B- | 2/5 | 4/5 | 2/5 | 3/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | B- | 2/5 | 4/5 | 2/5 | 3/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | B- | 2/5 | 4/5 | 2/5 | 3/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | B- | 2/5 | 4/5 | 2/5 | 3/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | B- | 2/5 | 4/5 | 2/5 | 3/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | C+ | 2/5 | 3/5 | 2/5 | 3/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | C+ | 2/5 | 3/5 | 2/5 | 3/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | C+ | 2/5 | 3/5 | 2/5 | 3/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | C+ | 2/5 | 3/5 | 2/5 | 3/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | B- | 2/5 | 3/5 | 2/5 | 3/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | B- | 2/5 | 3/5 | 2/5 | 3/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | B- | 2/5 | 3/5 | 2/5 | 3/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | B- | 2/5 | 3/5 | 2/5 | 3/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 9.3K | 0.26% |
| 2 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 4.1K | 0.48% |
| 3 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 460.3K | 0.06% |
| 4 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 739.82 | 0.22% |
| 5 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 2.2K | 0.22% |
| 6 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 1.2K | 0.22% |
| 7 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 527.52 | 0.22% |
| 8 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 60.99 | 0.22% |
| 9 | Vanguard Retirement Income ETF Portfolio VRIF.TO | 0.00% | 20.03 | 0.31% |
| 10 | Vanguard Conservative Income ETF Portfolio VCIP.TO | 0.00% | 9.54 | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bin Li | Vice President | — | male |
| Dehui Che | Vice President | — | male |
| Xihong Wang | Vice President | — | female |
| Xiujun Fan | Vice President | — | female |
| Xuewu Song | Vice President & Chief Financial Officer | — | male |
| Zhanjun Hou | President & Non-Independent Director | — | male |
| Zhiyu Huang | Vice President & Board Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 000931.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
